SupplementScience

Omega-3 Research & Evidence

DJP
Reviewed by , MD, Board Certified Internal Medicine

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Strong

Omega-3 fatty acids have an extensive evidence base spanning cardiovascular, neurological, and inflammatory conditions. The landmark REDUCE-IT trial (2019, NEJM, n=8,179) demonstrated that 4g/day of pure EPA reduced major adverse cardiovascular events by 25%. For mental health, a 2019 meta-analysis by Liao et al. in Translational Psychiatry confirmed that EPA-predominant formulas significantly reduce depressive symptoms. The relationship between DHA and brain structure is well-established, with DHA comprising a significant portion of brain fatty acids and declining with age.

Evidence by Condition

ConditionStudied DoseEvidence
Heart health1,000-2,000mg EPA+DHA daily; up to 4g EPA for high-riskStrong
Depression/mood1,000-2,000mg with EPA-predominant formula (>60% EPA)Strong
Joint pain2,000-3,000mg EPA+DHA dailyModerate
Brain health1,000mg DHA-predominant dailyModerate
Full Omega-3 Guide

References

  1. (). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. DOI
  2. (). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry. DOI
  3. (). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. DOI
  4. (). Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Frontiers in Aging Neuroscience. DOI